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Abstract 
Background: As a nation reduces the burden of falciparum malaria, identifying areas of transmission becomes 
increasingly difficult. Over the past decade, the field of utilizing malaria serological assays to measure exposure has 
grown rapidly, and a variety of serological methods for data acquisition and analysis of human IgG against falciparum 
antigens are available. Here, different immunoassays and statistical methods are utilized to analyse samples from a 
low transmission setting and directly compare the estimates generated.
Methods: A subset of samples (n = 580) from a 2012 Haitian nationwide malaria survey was employed as sample 
population of low falciparum endemicity. In addition to the Haitian samples, samples from 247 US residents were 
used as a reference population of ‘true seronegatives’. Data acquisition was performed through standard ELISA and 
bead-based multiplex assays assaying for IgG antibodies to the Plasmodium falciparum antigens MSP-1p19, MSP-
1p42(D), MSP-1p42(F), and AMA-1. Appropriate parametric distributions and seropositivity cutoff values were deter-
mined by statistical measures.
Results: Data from both assays showed a strong positive skew, and the lognormal distribution was found to be an 
appropriate statistical fit to the Haitian and American populations. The American samples served as a good serological 
true negative population for the multiplex assay, but not for ELISA-based data. Mixture model approaches to deter-
mine seronegative and seropositive populations from the Haitian data showed a high degree of distribution over-
lap—likely due to the historical low falciparum transmission in this nation. Different fittings to the reversible catalytic 
model resulted depending upon the immunoassay utilized and seropositivity cutoff method employed. Data were 
also analysed through fitting to penalized B-splines, presenting another possible analytical tool for the analysis of 
malaria serological data.
Conclusions: Standardization of serological techniques and analyses may prove difficult as some tools can prove to 
be more useful depending on the area and parasite in question, making clear interpretation a vital pursuit. The pre-
sented analysis in the low-endemic nation of Haiti found malaria-naive US residents to be an appropriate seronega-
tive reference population for the multiplex assay, and this assay providing consistent estimates between MSP-1 and 
AMA-1 antigens of percent seropositives for this low-endemic population.
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Background
Malaria caused by the apicomplexan parasite Plasmodium 
falciparum remains a significant global health concern 
with approximately 200 million cases and 600,000 deaths 
annually [1]. With the enormous burden P. falciparum 
has placed on humans and their ancestors, it is right-
fully stated that “malaria is the strongest known selective 
pressure in the recent history of the human genome” [2]. 
Besides the manipulations to the structure of haemoglo-
bin as a strategy to prevent malaria death, the human 
genome has also adapted to recognize numerous P. falci-
parum antigens as targets for a humoral response. Many 
of the most immunogenic antigens include membrane 
bound proteins that are found on the surface of invasive 
merozoites, which are released from infected erythrocytes 
following schizont-induced rupture of the host cell.
One of the important factors that determines an indi-
vidual’s carriage of memory B cells educated against 
P. falciparum antigens (and the serum IgG specific for 
these antigens) is age. If sustained transmission, no mat-
ter how low, is present in a geographical area, persons in 
that area have a greater cumulative risk of lifetime expo-
sure as they age. In regions of moderate or high transmis-
sion for P. falciparum, children progressing through their 
first decade of life show rapid increases in the acquisition 
of antibodies against the parasite [3–5]. The rate of sero-
logical development has been modelled by employing a 
reversible catalytic conversion model [6], which provides 
estimates for a population’s rates of antibody acquisition 
(seroconversion) as well as loss (seroreversion). The sero-
conversion rate for any particular antigen is due, in part, 
to the half-life of the memory B cell specific for the anti-
gen, and it has been hypothesized that as age and expo-
sure increase, so does the half-life and quantity of B cells 
specific for an antigen [7, 8]. A peculiar finding by many 
groups has shown that even in historically high trans-
mission zones, older age groups do not necessarily carry 
appreciable levels of long-lived IgG against P. falciparum 
[5, 9], even though multiple lifetime infections would have 
been nearly certain. Although the true explanation for this 
observation is likely multifaceted, one possibility involves 
the loss of antibodies over time through seroreversion [8].
As malaria incidence within an area decreases, the abil-
ity to detect active infections becomes increasingly diffi-
cult. The reduction of P. falciparum biomass within an area 
has been shown to relegate infections much more heavily 
towards sub-patent, sub-microscopic asymptomatic pres-
entations [10–12]. For nations initiating pre-elimination 
programmes, this greatly reduces the efficacy of transmis-
sion zone discovery through passive case detection [13]. 
Sensitive, nucleic acid-based technologies exist for the 
detection of low-parasitaemic infections, but are expensive, 
impractical for large sample sizes, and have been shown to 
vary widely in their lower limits-of-detection based on pro-
tocols and operators [9]. Furthermore, the window of time 
an individual could test positive is brief and based solely on 
a considerable amount of circulating parasites. More recent 
efforts have attempted to use serological markers as a proxy 
to estimate P. falciparum transmission intensity in areas 
with low parasite prevalence [6, 14, 15].
Many strategies have been utilized for the analysis and 
interpretation of malaria serological data. Unlike active 
infection detection which primarily focuses only on the 
presence or absence of infection, serological datasets can 
provide a wealth of information, especially when com-
bined with other covariates such as age. Recently, quanti-
tative immunoassays, such as ELISA and bead-based flow 
assays, have been the tests of choice, allowing relatively 
short sample preparation time and robust data genera-
tion. In addition, multiple methods have been employed 
with efforts to maintain the continuous nature of the data 
as well as dichotomize the sample population into classes 
of ‘seropositive’ or ‘seronegative’. When dichotomizing 
variables, further various approaches have been used in 
order to determine an assay value at which the data can 
be partitioned—generally referred to as the cutoff value. 
Here is presented analyses of serological data from a 
region of low P. falciparum endemicity by comparison of 
immunoassays, variable classifications, and cutoff value 
determinations. Data is also presented from a large sam-
ple of persons never exposed to malaria to show IgG dis-
tributions in a malaria-naive population.
Methods
Ethical considerations
The survey protocol was approved by CDC’s internal 
review board and the Haiti ethical review committee in 
2012 at the Ministry of Health. All persons participat-
ing in the survey were assigned a six-digit identification 
number that could not be traced back to the individual.
Survey design and sample collection
Samples from persons assumed to have never been 
infected with malaria were gathered from blood donated 
to a community blood bank in Memphis, TN, USA. All 
blood units were from persons that had screened nega-
tive for HIV and hepatitis B viruses and had no reported 
history of international travel in the six previous months.
For the area of low P. falciparum endemicity, a track-
ing results continuously (TRaC) survey was conducted 
in 2012 as part of Global Fund’s Round 8 activities that 
builds on the Strategic Plan against Malaria in Haiti. 
A 2011 nationwide survey reported Haiti to have a low 
national parasite prevalence of less than 1 % as estimated 
by PCR [16]. The 2012 survey was cross-sectional and 
implemented by Population Services International (PSI) 
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utilizing a community-based household design in col-
laboration with Haiti’s Ministry of Health (MSPP) and 
the Centers for Disease Control and Prevention (CDC). 
Dried blood spots (DBS) were obtained for each indi-
vidual consenting to participate by spotting finger-prick 
blood onto Whatman 903 Protein Saver Cards or What-
man 1 circular filter paper (GE Healthcare, Piscataqway, 
NJ, USA), and air drying for at least 2  h. Samples were 
individually packaged into plastic bags with desiccant 
and stored at 4  °C prior to analysis. For this study, 580 
samples were randomly selected which represented 12 % 
of the TRaC 2012 sample population. In line with previ-
ous national estimates, this subset of samples was found 
to have a parasite prevalence of under 1 %.
Blood spot elution and immunoassays
A 6  mm circular punch was taken from the centre of 
each blood spot, corresponding to 14  μL whole blood, 
for elution. Samples were shaken overnight at room tem-
perature in 140 μL protein elution buffer containing: PBS 
(pH 7.2), 0.05  % Tween-20, 0.05  % sodium azide, and 
stored at 4  °C until analysis. Elution from blood spots 
provided an initial 1:10 dilution, and samples were fur-
ther diluted 1:40 in ELISA or Luminex sample diluent for 
a final whole blood dilution of 1:400, corresponding to a 
serum dilution of approximately 1:800 with the assump-
tion of 50 % haematocrit in whole blood. Three P. falci-
parum merozoite surface protein 1 (MSP-1) fragments 
were employed, including two allelic forms of the 42kD 
fragment of MSP-1: MSP-1p42(D) and MSP-1p42(F) 
from the 3D7 and FVO strains, respectively, and one 
form of the 19  kD fragment (MSP-1p19) fused to glu-
tathione S-transferase (GST) cloned from P. falciparum 
isolate 3D7. The sequence encoding the MSP-1p19 frag-
ment previously described by Burghaus and Holder [17] 
was PCR amplified from 3D7 parasite strain genomic 
DNA using the following forward and reverse deoxyo-
ligonucleotides: 5′-CGC GGA TCC AAC ATT TCA 
CAA CAC CAA TGC GTA-3′ and 5′-GCG GAA TTC 
TTA GTT AGA GGA ACT GCA GAA AAT ACC-3′, 
respectively. The BamHI and EcoRI restriction endonu-
clease sites used for directional cloning into pGEX 4T-2 
(GE Healthcare) are underlined in the sequences, and an 
in-frame stop codon (italics) was included in the reverse 
primer. Standard protocols for PCR amplification, clon-
ing into BL21 strain Escherichia coli (Stratagene, LaJolla, 
CA), expression, and purification of a GST fusion protein 
product have previously been reported [18, 19]. Fusion 
protein eluted from the glutathione Sepharose 4B affin-
ity column (GE Healthcare) was dialyzed against 25 mM 
Tris buffer at pH 7.5 as previously described [20] and 
loaded onto a MonoQ HR 5/5 strong anion exchange 
column (GE Healthcare) previously equilibrated with 
25  mM Tris buffer at pH 7.5. The column was washed 
up to 0.2 M NaCl in 25 mM Tris buffer at a flow rate of 
1  mL/min, and then the bound GST-MSP-1p19 fusion 
protein was eluted with a 5 min linear gradient from 0.2 
to 0.5 M NaCl in Tris buffer. The fractions that included 
a large absorbance peak centered at ~0.3  M NaCl were 
combined, dialyzed overnight at 4 °C against 500 volumes 
of buffer containing 0.85 % NaCl and 10 mM Na2HPO4 at 
pH 7.2 (PBS) (Spectra/Por 3 dialysis membrane, 3500 Da 
cutoff, Spectrum Laboratories, Rancho Dominguez, CA, 
USA), and concentrated using a Centricon-10 centrifugal 
filter device (Millipore Corporation, Bedford, MA, USA). 
The final concentration of the GST-MSP-1p19 fusion 
protein was >0.5 mg/mL (BCA microassay, Pierce, Rock-
ford, IL, USA) with a yield of approximately 0.25  mg/L 
of E. coli culture. The external domain of Apical Mem-
brane Antigen-1 (AMA-1) and MSP-1p42 antigens were 
produced at Walter Reed Army Institute of Research 
(WRAIR) under previously published conditions [21].
Before analysis, ELISA assays were optimized for anti-
gen coating concentration and dilution of horseradish 
peroxidase (HRP) conjugate to reduce background signal 
while still providing strong detection of the specified IgG. 
After optimization, all samples were run under the same 
conditions using a standard in-house protocol. Briefly, 
Immulon 2 HB plates (ThermoFisher Scientific, Waltham, 
MA, USA) were coated with 100 μL of 0.25 μg/mL anti-
gen in PBS overnight at 4 °C and then blocked for 2 h the 
next day with 5  % non-fat milk in PBS, 0.05  % Tween-
20 (PBS-T, Sigma-Aldrich, St. Louis, MO, USA). Sam-
ples were diluted in blocking buffer, added in duplicate 
at 100  μL/well, and incubated for 2  h with gentle shak-
ing. An HRP-conjugated secondary antibody (goat anti-
human IgG) was diluted 1:12,000 in PBS-T, and 100  μL 
added for 1 h. For each well, 100 μL peroxidase substrate 
(KPL, West Chester, PA, USA) was added and color 
allowed to develop for 10 min. The reaction was stopped 
by adding 100 μL 0.2 M H2SO4 and plates read on a spec-
trophotometer (Molecular Devices SpectraMAX, Sunny-
vale, CA, USA) at 450 nm. Positive and negative control 
wells were included on each plate to ensure consistency 
between readings. At the end of the study, any particular 
plate was re-run if its controls showed 25 % or more vari-
ation among all plates performed for the study.
The same DBS elutions were also assayed using 
bead-based multiplex technology. Antigens were cou-
pled to BioPlex® COOH beads (BioRad, Hercules, CA, 
USA) according to manufacturer’s protocol in the pres-
ence of 50  mM 2-(4-morpholino)-ethane sulfonic acid, 
0.85  % NaCl at pH 5.0 and an antigen concentration of 
20  μg/mL for all antigens. Sulfo-NHS was purchased 
from ThermoFisher and EDC from Sigma-Aldrich. As 
a control to test for any serum IgG against GST for the 
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GST-MSP-1p19 fusion protein, a bead was included 
in the panel which was coupled to GST. Samples were 
diluted in blocking buffer containing 0.5  % Polyvinyl 
alcohol (Sigma), 0.8  % Polyvinylpyrrolidine (Sigma), 
0.1  % casein (ThermoFisher), 0.5  % BSA (Millipore), 
0.3 % Tween-20, 0.1 % sodium azide, and 0.01 % E. coli 
extract to prevent non-specific binding. Reagent dilu-
ent (Buffer C) consisted of PBS-T plus 0.5 % BSA, 0.02 % 
sodium azide. Filter bottom plates (Multiscreen 1.2 μm, 
Millipore) were pre-wetted with PBS-T and 1500 beads/
analyte incubated with sample in duplicate for 1.5  h 
under gentle shaking. Secondary antibodies tagged with 
biotin (1:500 anti-human IgG1–3, Southern Biotech, Bir-
mingham, AL, USA; 1:2500 anti-human IgG4, Sigma) 
were incubated for 45  min, and subsequent incubation 
with streptavidin–phycoerythrin (1:200, Invitrogen) 
for 30 min. Plates had a final wash incubation with rea-
gent diluent for 30 min and were read on a Bio-Plex 200 
machine by generating the median fluorescence signal 
for 50 beads/analyte and then the mean fluorescence 
intensity (MFI) between the duplicate wells. Final MFI 
was reported for a sample after subtracting MFI values 
from blank background beads that were included on each 
plate.
Statistical analyses
Data were fitted to parametric distributions by statisti-
cal software programs SAS 9.3, StataSE 13, and R 3.1.2 
and means and standard deviations estimated. Statisti-
cal appropriateness of fitted distributions was performed 
in the SAS software package with the PROC UNIVARI-
ATE procedure and HISTOGRAM statement. The null 
hypothesis of the Anderson–Darling, Cramér–von Mises, 
and Kolmogorov–Smirnov tests is that the data of inter-
est are appropriate for the distribution of interest, so a P 
value of >0.05 would indicate a statistically-acceptable fit. 
The analysis relaxed the stringency to a P value of >0.01 
in order to be inclusive for more tests for the purpose of 
comparisons between immunoassays and among anti-
gens. When considering malaria-naive US residents as a 
reference population, extreme outliers could significantly 
affect the statistical nature of distributions, so any opti-
cal density value (OD) >0.3 or MFI >250 was eliminated 
from the ‘true negative’ analysis. The number of remov-
als for each antigen and each immunoassay is listed in 
Additional file 1. No individual had more than one value 
removed for readings on all antigens.
Finite mixture regression models were fitted to the 
dataset by StataSE’s fmm and R’s flexmix command, 
as well as SAS’s PROC FMM. All use maximum likeli-
hood estimation to fit an unweighted two-component 
model of ‘seronegatives’ and ‘seropositives’. The mean and 
standard deviation were collected from the seronegative 
component and used for further statistical analysis. Sero-
prevalence curves and estimates for seroconversion and 
seroreversion rates were based on fitting data to a revers-
ible catalytic model as described previously [6].
Continuous data were fitted to penalized B-splines for 
both ELISA and Luminex assays. A B-spline allows a 
defined number of connected polynomial functions to be 
fitted to a continuous variable. A cubic function (degree 
of 3) with 50 knots was used to generate each spline and 
a very high penalty function (λ = 1,000,000) was imposed 
to prevent high variation between knots and allow curve 
smoothing.
Results
Since readings for immunoassays can vary widely 
depending on reagents and protocols, it was investigated 
how ELISA and multiplex assays performed when the 
same dilution series was ran using the specified reagents 
and protocols that would be employed for the entire 
study. As MSP-1 and AMA-1 antigens are thought to 
induce robust and long-lived humoral immune responses 
after multiple exposures to malaria infection [8, 22, 23], 
blood was pooled from individuals residing in a Kenya 
region holoendemic for P. falciparum malaria, spotted 
onto filter paper, eluted, and titrated using each immu-
noassay. Through the ELISA assay, high IgG concentra-
tions in Kenyan blood allowed samples to be diluted to 
1:105-fold before reaching the lower asymptote of the sig-
moidal curve (Additional file 2), but the multiplex assay 
allowed further titration capacity. This observation has 
been reported in other falciparum malaria studies, which 
have found bead-based multiplex assays provided higher 
titration capacity when directly compared with ELISA 
[24, 25]. Possible explanations for this finding include the 
3-dimensional nature of the bead assay as well as the abil-
ity of flow cytometry emission detectors to read a wide 
range of fluorescence intensities.
One of the common approaches to analysing sero-
logical data includes classifying persons in a sample as 
either ‘seropositive’ or ‘seronegative’ depending upon 
IgG titres to a specific P. falciparum antigen. This use-
ful method can simplify interpretation and allow direct 
comparisons among sampling areas [6, 9] or time points 
[26] of interest. However, due to the inherent back-
ground signal from a blood or serum sample, multiple 
methods have been devised in order to determine at 
which signal intensity an individual should be consid-
ered seropositive [6, 14, 27, 28]. A reference population 
is commonly used to determine the whole blood, serum, 
or DBS elution background signal for the immunoassay, 
reagents, and protocol in practice. Ideally, this refer-
ence population would be derived at the sampling site 
from individuals known to never have been exposed to 
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malaria, but since this is practically impossible, Euro-
peans or Americans with no history of travel to malaria 
endemic countries typically act as the non-immune ref-
erence. For this study, 247 US residents were used as a 
non-immune reference to indicate the ‘true negative’ 
sero-distribution for each antigen. Distributions for 
both immunoassays and all four antigens showed a very 
similar pattern of positively-skewed data which visu-
ally fit poorly to normal (Gaussian) distribution (Fig. 1). 
When attempting to fit the data to various parametric 
distributions which assume a positive skew, it was found 
that ELISA data were statistically appropriate for many 
distributions, whereas Multiplex data were not (Addi-
tional file 3). This is likely due to the high positive values 
for both kurtosis and skewness for the Multiplex data. 
Notably, the normal distribution was not an appropriate 
statistical fit for any of the malaria-naive data on either 
immunoassay. As the lognormal distribution was found 
to be most appropriate for ELISA data, and showed a 
good visual fit to Multiplex data (Fig.  1), this was the 
only non-normal distribution of interest for the remain-
der of the study.
Fig. 1 Histograms of samples from malaria-naive persons (n = 247) as analysed by ELISA and Luminex assays. Charts are overlaid with normal (solid 
line) and lognormal (dashed line) fitted curves. The x-axes are truncated to the upper limit of the observed data: OD units, 0.25; MFI units, 240
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Inspection of the immunoassay signal distribution for 
persons from an area of low P. falciparum transmission 
showed a very similar depiction with a large percentage 
of the sample population congregating on the low end of 
the x-axis (Fig. 2), a finding also seen in other studies [27, 
29, 30]. Direct comparison of an individual’s signal for 
both immunoassays yielded a strong positive correlation 
and high agreement between assays (Additional file  4). 
The initial method of determining a seropositivity cut-off 
utilized the ‘classical approach’ [28] with malaria-naive 
population as a reference group and the mean plus stand-
ard deviations providing a cutoff value. Overlay of his-
tograms from Fig.  1 (malaria-naive) onto Fig.  2 (sample 
population) showed clear overlap in the highest density 
of the sample distributions for the Multiplex assay with 
less than five MFI units separating the peaks of the two 
histograms (Fig.  3). However, the overlay of ELISA his-
tograms did not show a similar pattern, indicating that 
malaria-naive US residents were likely a less suitable ref-
erence population for ELISA data. A key assumption in 
Fig. 2 Histograms of samples (n = 580) from a region of low-endemic P. falciparum transmission. The x-axes display the entire dynamic range of 
each assay. OD units, 0–3.5; MFI units, 0–30,000
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using the serodistribution of a malaria-naive population 
is that their blood/serum is representative of the sample 
population—just lacking IgG antibodies against malaria 
antigens. If using a malaria-naive population as a refer-
ence, an adequate panel of samples should be run to visu-
ally inspect the overlap between the sample and reference 
populations. Data presented in this study specifically pro-
vides comparison between populations in a malaria-naive 
and low-endemic settings using specific assay conditions 
for ELISA and Multiplex (see “Methods”). Previously 
published studies utilizing different assay variations to 
determine seropositivity cutoffs for sample populations 
(of varying endemicity) may have found US or European 
residents to be an appropriate malaria-naive population 
for that particular study. To this point, it is of value to sta-
tistically investigate a malaria-naive reference population 
under each study’s particular conditions. For this study’s 
malaria-naive population, the mean signal and standard 
deviations for all four antigens were generated for both 
immunoassays and for both normal and lognormal dis-
tributions (Table  1). Frequently, the mean signal plus 
three or five standard deviations is designated as a sero-
positivity cutoff with a high degree of confidence [6, 14, 
31]. When comparing normal to lognormal distributions, 
Fig. 3 Overlay of histogram from malaria-naive population (grey bars), on sample population (open bars). The x-axis for both immunoassays is trun-
cated as in Fig. 1 to show comparative overlay
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ELISA data gave almost identical cutoff values, where 
Multiplex cutoff values were slightly more conservative 
under a normal distribution.
An additional strategy for determining a cutoff value 
is the implementation of the finite mixture regression 
model (FMM), which aims to identify an indicated mix-
ture of densities using maximum likelihood estimation 
(MLE). Normal and lognormal distributions were speci-
fied for each antigen’s data and attempted to fit to a two-
component mixture (Additional file 5). The FMM ELISA 
cutoff values were much higher under both distributions 
when compared with values garnered from the malaria-
naive population (Table  1). Interestingly, FMM cutoff 
values were only slightly less conservative for Multiplex 
data under a normal distribution when compared to the 
malaria-naive population, but quite lower under a lognor-
mal distribution. An innate assumption of finite mixture 
model regression is that the number of true components 
is known a priori [32], even if a parametric distribution is 
not assumed. In biological reality, it is unlikely that only 
two components exist: a seronegative and a seroposi-
tive, if true definable components exist at all. Numerous 
true distributions may exist depending on genotype (host 
and parasite), age of infection, and co-infections, among 
many other factors. As the seropositivity cutoff values 
varied greatly depending on statistical method used, the 
amount and percentage of the sample population that 
would be considered ‘seropositive’ also varied (Table 2). 
Since all three MSP-1 fragments showed high correlation 
among each other in signal intensity, the MSP-1p19 anti-
gen estimates are used as the MSP-1 representative.
When seropositivity is coupled with age data for 
a sample population, estimates are able to be calcu-
lated for the rates of acquiring (seroconversion) or 
loss of (seroreversion) IgG antibodies against a patho-
gen by fitting data to a reversible catalytic conversion 
model [6, 9, 33]. Younger age groups are important for 
this model, as the first years of life represent the most 
dynamic period of antibody acquisition. For falcipa-
rum malaria, seroconversion rates have been shown 
to correlate with entomological inoculation rates [6], 
and diminish with successful malaria control interven-
tions [5, 34]. When using the malaria-naive population 
as a reference, seroprevalence curves generated by the 
catalytic model tended to vary more by immunoassay, 
rather than which parametric distribution was specified 
(Fig. 4a). This finding was also reflected in the estimated 
seroconversion (λ) and seroreversion (ρ) rates (Addi-
tional file  6). When moving to a higher stringency of 
mean plus five standard deviation seropositivity cutoff, 
ELISA estimates were greatly reduced, whereas Multi-
plex estimates largely remained unchanged. When the 
FMM strategy was used to generate seropositivity cutoff 
values, different parametric distributions gave dissimilar 
Table 1 Means, standard deviations, and seropositivity cutoff values for each antigen as determined by different immu-
noassays and statistical methods
Distribution, assay Antigen Malaria-naïve reference population Finite mixture model, first component
Mean (SD) Mean + 3SD Mean + 5SD Mean (SD) Mean + 3SD Mean + 5SD
Normal distribution
 ELISA (in OD) MSP1-42(D) 0.045 (0.027) 0.126 0.180 0.125 (0.069) 0.332 0.470
MSP1-42(F) 0.030 (0.019) 0.087 0.125 0.127 (0.068) 0.331 0.467
MSP1-19 0.052 (0.025) 0.127 0.177 0.157 (0.080) 0.397 0.557
AMA-1 0.056 (0.038) 0.170 0.246 0.14 (0.069) 0.347 0.485
 Multiplex (in MFI) MSP1-42(D) 10.7 (21.2) 74.3 116.7 18.3 (16.7) 68.4 101.8
MSP1-42(F) 16.4 (29.1) 103.7 161.9 21.7 (22.4) 88.9 133.7
MSP1-19 11.1 (10.7) 43.2 64.6 11.4 (10.5) 42.9 63.9
AMA-1 15.3 (19.0) 72.3 110.3 21.7 (23.5) 92.2 139.2
Lognormal distribution
 ELISA (in OD) MSP1-42(D) 0.045 (0.027) 0.126 0.180 0.085 (0.572) 1.801 2.945
MSP1-42(F) 0.030 (0.021) 0.093 0.135 −1.214 (1.242) 2.512 4.996
MSP1-19 0.052 (0.026) 0.130 0.182 0.377 (0.385) 1.532 2.302
AMA-1 0.056 (0.037) 0.167 0.241 0.292 (0.500) 1.792 2.792
 Multiplex (in MFI) MSP1-42(D) 10.1 (17.0) 61.1 95.1 2.5 (0.96) 5.4 7.3
MSP1-42(F) 15.3 (21.6) 80.1 123.3 2.5 (0.69) 4.6 6.0
MSP1-19 10.9 (9.8) 40.3 59.9 2.0 (0.84) 4.5 6.2
AMA-1 15.0 (16.6) 64.8 98.0 2.5 (0.91) 5.2 7.1
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Table 2 Number and percentage of sample population (n = 580) considered seropositive for MSP-1-19 and AMA-1 anti-
gens when applying different cutoff criterion
Assay Antigen Malaria-naïve reference population Finite mixture model
Mean + 3SD Mean + 5SD Mean + 3SD Mean + 5SD
Normal distribution
 ELISA MSP-1 362 (62.4 %) 251 (43.3 %) 66 (11.4 %) 41 (7.1 %)
AMA-1 197 (34.0 %) 81 (14.0 %) 38 (6.6 %) 25 (4.3 %)
 Multiplex MSP-1 126 (21.7 %) 105 (18.1 %) 126 (21.7 %) 105 (18.1 %)
AMA-1 108 (18.6 %) 76 (13.1 %) 90 (15.5 %) 71 (12.2 %)
Lognormal distribution
 ELISA MSP-1 355 (61.2 %) 238 (41.0 %) 15 (2.6 %) 5 (0.9 %)
AMA-1 200 (34.5 %) 87 (15.0 %) 5 (0.9 %) 1 (0.2 %)
 Multiplex MSP-1 130 (22.4 %) 110 (19.0 %) 451 (77.8 %) 403 (69.5 %)
AMA-1 120 (20.7 %) 85 (14.7 %) 468 (80.7 %) 421 (72.6 %)
Fig. 4 Seroprevalence curves for MSP-1 and AMA-1 antigens based on different immunoassays, fitted distributions, and seropositive cutoff determi-
nations. The MSP-1p19 antigen was chosen to represent MSP-1 response as a whole. Curves represent ELISA (black lines) and multiplex assays (grey 
lines) with normal (solid lines) and lognormal (dashed lines) distributions. Seropositivity was based on mean + 3SD cutoff value for all comparisons. 
a Curves generated when using malaria-naive persons as reference. Note ELISA normal and lognormal seroprevalence curves for the MSP-1 antigen 
overlap. b Curves generated by finite mixture model approaches
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results for seroprevalence curves (Fig. 4b) and sero-rates 
(Additional file  6). Although the FMM approach has 
shown to be quite useful in areas of varying degrees of 
P. falciparum transmission, potential disadvantages of 
this method in settings of very low historical transmis-
sion include the high overlap between seropositive and 
seronegative populations (illustrated in [28]) and esti-
mates of seroreversion rates that are higher than the 
estimated seroconversion rate. Methods for determin-
ing seropositivity cutoffs become more of a moot point 
when comparisons are made only within a defined study 
where the same immunoassay, reagents, and protocols 
are employed for all samples. In fact, it may be suitable 
to choose any value within the ‘indeterminate range’ 
[33] for comparisons within a single study, as long as 
no evidence exists that different people groups have 
dissimilar background signal intensities. When apply-
ing new technology or techniques to an area which has 
already had multiple sero-surveys, it may be necessary 
to not apply too much weight to the magnitude of the 
‘percent seropositive’ or seroconversion rate estimates, 
but rather provide relative comparisons among differ-
ent regions within a geographical area. To truly compare 
estimates among different malaria sero-studies, an inter-
national serological gold standard may be appropriate, as 
is the practice for various other diseases [35–37]. A gold 
standard serum could also provide a means by which to 
calibrate a research group’s unique immunoassay to des-
ignate the seropositivity cutoff of the OD or MFI value at 
‘X’ international units.
Since transforming continuous data to binary results 
in an inherent loss of information, data were also ana-
lysed by maintaining immunoassay signal intensities. 
High IgG titres against P. falciparum antigens would be 
the likely result of active or recent parasite exposure, 
or evidence of multiple exposures throughout life [38]. 
Penalized B-splines were fitted for each antigen within 
each immunoassay, and area under the curve (AUC) 
calculated (Fig. 5). The shapes of all B-splines were very 
similar, with increases in the predicted signal intensity 
as persons progress through the first 30 years of life, fol-
lowed slight declines in the 50s and 60s. A decrease in 
IgG titres for these ages has been observed elsewhere for 
the AMA-1 antigen [39], but MSP-1 serology has shown 
maintenance of high titres throughout life. By percent-
age, AUC values within the ELISA assay were similar, 
with the AMA-1 curve showing the greatest AUC devia-
tion from the mean of 13  %. Multiplex B-splines were 
much more varied with the MSP-1p19 spline showing 
the greatest AUC deviation of 36 % from the mean. Due 
to the integral differences between the two immunoas-
says, AUC comparisons would be incompatible, but 
assessments within an assay of different time points or 
geographical areas could potentially yield productive 
comparisons.
Conclusions
Malaria serological data have shown great potential for 
the elucidation of varying transmission regions within an 
area. Numerous Plasmodium and vector antigens have 
been well characterized, and multivariate approaches to 
malaria serology may yield robust analyses in the future. 
As P. falciparum exposure incidence is reduced in a 
population, levels of IgG against falciparum will reduce 
as well, and defining what constitutes an individual as 
seropositive becomes more difficult. Here, direct com-
parisons are presented of multiple methods for acquiring 
and analysing falciparum serological data from an area of 
low P. falciparum endemicity. It was found that the Mul-
tiplex bead assay provided a higher titration capacity, and 
a denser histogram of data when used to generate assay 
from a low-endemic sample population. Additional anal-
yses found that a malaria-naive sample set was an appro-
priate reference when using a bead-based assay and that 
ELISA estimates for seropositives within a population 
varied greatly depending on the method used to develop 
a seropositivity cutoff value. The novel method of apply-
ing B-splines to serological data provides an additional 
technique for displaying this type information.
Fig. 5 Penalized B-splines fitted to continuous data for each antigen 
MSP-1p42(D) no markers; MSP-1p42(F) square markers; MSP-1p19 
triangle markers; AMA-1 circle markers. Inset box displays area under 
the curve (AUC) calculations for each antigen by each assay
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